FDA Panel Mulls Approval Of Sirion’s Durezol
This article was originally published in The Pink Sheet Daily
Advisory committee will consider topical ophthalmic steroid for postoperative ocular inflammation and pain on May 29.
You may also be interested in...
Sirion Postoperative Ocular Inflammation Candidate Durezol Shows Efficacy In Twice-Daily Dosing In Phase III Study
Topical steroid has June 26 FDA action date.
CEO Butler tells “The Pink Sheet” DAILY Durezol would improve on the current standard of care by offering twice-daily dosing for post-operative ocular inflammation.
The International Fragrance Association North America took a break from its higher-stakes advocacy work Nov. 1 to give lawmakers and congressional staffers a "scent experience." Perfumers from six of the group's biggest members were on hand with "Scents of Home," joined by Monell Center researchers to educate attendees on the mechanics of scent and the important role it plays in people's lives.